# Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.

> **NCT06311942** · PHASE4 · RECRUITING · sponsor: **Chen Xiaoping** · enrollment: 300 (estimated)

## Conditions studied

- HCC

## Interventions

- **DRUG:** HAIC plus PD-1 inhibitors plus lenvatinib
- **DRUG:** PD-1 inhibitors plus lenvatinib

## Key facts

- **NCT ID:** NCT06311942
- **Lead sponsor:** Chen Xiaoping
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2024-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06311942

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06311942, "Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06311942. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*